TMCnet News
Amgen Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Amgen Inc. of Deadline in Securities Fraud Class Action LawsuitThe law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Amgen's materially misleading statements and omissions to the public, Amgen's investors have suffered significant losses. CLICK HERE TO SUBMIT YOUR AMGEN LOSSES. YOU CAN ALSO CLICK ON THE FOLLOWING LINK OR COPY AND PASTE IN YOUR BROWSER: https://www.ktmc.com/new-cases/amgen-inc?utm_source=PR&utm_medium=link&utm_campaign=amgn&mktm=r TO VIEW OUR VIDEO, PLEASE CLICK HERE LEAD PLAINTIFF DEADLINE: MAY 12, 2023 CLASS PERIOD: JULY 29, 2020 THROUGH APRIL 27, 2022
CONTACT AN ATTORNEY TO DISCUSS YOUR RIGHTS:
Kessler Topaz is one of the world's foremost advocates in protecting the public against corporate fraud and other wrongdoing. Our securities fraud litigators are regularly recognized as leaders in the field individually and our firm is both feared and respected among the defense bar and the insurance bar. We are proud to have recovered billions of dollars for our clients and the classes of shareholders we represent.
AMGEN'S ALLEGED MISCONDUCT
Then, on August 3, 2021, Amgen disclosed, for the first time, massive outstanding tax liabilities sought by the IRS. The release stated that Amgen had received a Notice of Deficiency from the IRS in July 2021 which sought $3.6 billion in back taxes, plus interest, for tax years 2010, 2011, and 2012. Following this news, the price of Amgen common stock fell by more than 6%. Then, on April 27, 2022, Amgen issued an earnings release for its first fiscal quarter of 2022, which disclosed that Amgen had received a Notice of Deficiency from the IRS in April 2022 which sought $5.1 billion in back taxes, plus interest, for tax years 2013, 2014, and 2015, and proposed a $2 billion penalty as a result of Amgen's improper tax avoidance strategies. Following this news, the price of Amgen common stock fell by an additional 4.3%, to close at $238.13 on April 28, 2022.
WHAT CAN I DO?
CLICK HERE TO SIGN UP FOR THE CASE
WHO CAN BE A LEAD PLAINTIFF?
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005050/en/ |